These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

735 related items for PubMed ID: 19101898

  • 1. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H, Kor K, Djalali M.
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [Abstract] [Full Text] [Related]

  • 2. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 3. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH.
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [Abstract] [Full Text] [Related]

  • 4. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW, DU LL, Zhao XW, Jing JX, Han CZ, Cui Y, Liu JW, Hao HL, Wang ZG, Mi ZG.
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [Abstract] [Full Text] [Related]

  • 5. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI.
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [Abstract] [Full Text] [Related]

  • 6. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 Sep; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 7. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.
    Cancer; 2006 Apr 15; 106(8):1701-7. PubMed ID: 16541433
    [Abstract] [Full Text] [Related]

  • 8. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F.
    Cytopathology; 2008 Dec 15; 19(6):369-74. PubMed ID: 18631356
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Dec 15; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug 15; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 11. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI.
    J Urol; 2005 May 15; 173(5):1518-25. PubMed ID: 15821471
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R.
    Anticancer Res; 2000 May 15; 20(2B):1169-72. PubMed ID: 10810416
    [Abstract] [Full Text] [Related]

  • 13. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.
    Anticancer Res; 1999 May 15; 19(4A):2621-3. PubMed ID: 10470205
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar 15; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May 15; 24(7):829-36. PubMed ID: 9170521
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.